This present disclosure relates to the use of syncytiotrophoblast-derived microvesicles for diagnosing and/or monitoring a subject with preeclampsia. Accordingly, this disclosure provides for methods for isolating, purifying, and/or detecting syncytiotrophoblast-derived microvesicles from a biological fluid of a pregnant subject. The present disclosure also provides kits for diagnosing a subject with preeclampsia, where the kit contains reagents useful for isolating, purifying, and/or identifying the syncytiotrophoblast-derived microvesicles in a biological sample and for detecting one or more biomarkers present on the surface of or within the syncytiotrophoblast-derived microvesicles.

This present disclosure relates to the use of syncytiotrophoblast-derived microvesicles for diagnosing and/or monitoring a subject with preeclampsia. Accordingly, this disclosure provides for methods for isolating, purifying, and/or detecting syncytiotrophoblast-derived microvesicles from a biological fluid of a pregnant subject. The present disclosure also provides kits for diagnosing a subject with preeclampsia, where the kit contains reagents useful for isolating, purifying, and/or identifying the syncytiotrophoblast-derived microvesicles in a biological sample and for detecting one or more biomarkers present on the surface of or within the syncytiotrophoblast-derived microvesicles.

The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.

The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.

Provided is an antibody or antibody fragment. The antibody or the antibody fragment includes HCDR1 selected from GYTFSSFS, GYTFSTFA, or GYSFTAYT, HCDR2 selected from ILPGSNST, ILPGINNT, ILPGGNNT, or INPYNGGT, and HCDR3 selected from SSYWFAY, STYWFAY, or AREGNYYGSRGDFDY; and LCDR1 selected from QSLLNSGNQKNY or QTIVTN, LCDR2 selected from GAS or YAS, and LCDR3 selected from QNAHSYPPT, QNAHSYPPA, or QQSHSWPFT. The provided antibody can be used for treating cancer.

The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Methods of assessing the efficacy of an agent in treating a disease or disorder are provided that include determining whether the agent causes, or inhibits, direct or indirect recruitment and/or ubiquitination and/or degradation of argininosuccinate synthetase 1 (ASS1).